title: Results of treatment of malignant germ cell tumors in 93 children: a report from the Childrens Cancer Study Group.
abstract: We report treatment results in 93 children entered on study from 1978 to 1984 with malignant germ cell tumors (MGCTs), excluding dysgerminoma and tumors of the testis or brain. The estimated 4-year survival and event-free survival (EFS) for all 93 patients were 54% and 49%, respectively. For 30 children with ovarian tumors, the estimated 4-year survival was 67% and EFS was 63%. For 63 children with nongonadal tumors, survival and EFS were 48% and 42%, respectively. The comparison of EFS between ovarian and nongonadal tumors was significant at P = .03. The treatment plan included a second-look surgical procedure after 18 weeks of chemotherapy. Over half of 36 patients evaluated as having a residual mass present immediately before second-look surgery had no malignant tumor after review of surgical specimens. Age greater than 11 years at diagnosis, incomplete removal of tumor at first surgery, and more than one structure or organ involved at diagnosis increased the risk for adverse event. The histologic subtype of the primary tumor was not related to outcome. Diagnosis was verified by independent pathologic review, and treatment was uniform. Seventeen percent of all registered patients (21 of 127) were excluded because of ineligible pathologic diagnoses; sixty percent (13 of 21) were immature teratomas.
authors.affiliation: University of California, San Francisco.
authors.forename: A R
authors.initials: AR
authors.lastname: Ablin
authors.forename: M D
authors.initials: MD
authors.lastname: Krailo
authors.forename: N K
authors.initials: NK
authors.lastname: Ramsay
authors.forename: M H
authors.initials: MH
authors.lastname: Malogolowkin
authors.forename: H
authors.initials: H
authors.lastname: Isaacs
authors.forename: R B
authors.initials: RB
authors.lastname: Raney
authors.forename: J
authors.initials: J
authors.lastname: Adkins
authors.forename: D M
authors.initials: DM
authors.lastname: Hays
authors.forename: D R
authors.initials: DR
authors.lastname: Benjamin
authors.forename: J L
authors.initials: JL
authors.lastname: Grosfeld
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003609:Dactinomycin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D009373:Neoplasms, Germ Cell and Embryonal / Q000628:therapy*; D011379:Prognosis; D012086:Reoperation; D016019:Survival Analysis; D014747:Vinblastine / Q000008:administration & dosage
chemical_list: D001761:Bleomycin; D003609:Dactinomycin; D014747:Vinblastine; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin